Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study

Journal of Affective Disorders

Volumn 197, Issue , 2016, Pages 51-57

  Ketter, Terence A ^a   Amchin, Jess ^b   Frye, Mark A ^c   Gross, Nicholas ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

^c MAYO CLINIC   (United States)

Author keywords

Armodafinil; Bipolar depression; Bipolar I disorder; Long term safety; Wakefulness

Indexed keywords

ARIPIPRAZOLE; ARMODAFINIL; LAMOTRIGINE; LITHIUM; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZOLPIDEM; BENZHYDRYL DERIVATIVE; WAKEFULNESS PROMOTING AGENT;

ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; BACKACHE; BIPOLAR DEPRESSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RHINOPHARYNGITIS; SOMNOLENCE; YOUNG MANIA RATING SCALE; AGED; ANXIETY; BIPOLAR DISORDER; CHEMICALLY INDUCED; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANXIETY; BENZHYDRYL COMPOUNDS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; WAKEFULNESS-PROMOTING AGENTS;

EID: 84960102820     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2016.02.050     Document Type: Article

References (33)

1. B. Ahrens, B. Muller-Oerlinghausen, M. Schou, T. Wolf, M. Alda, E. Grof, P. Grof, G. Lenz, C. Simhandl, and K. Thau Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis J. Affect. Disord. 33 1995 67 75
2. R.J. Baldessarini, M. Pompili, and L. Tondo Suicide in bipolar disorder: risks and management CNS Spectr. 11 2006 465 471
3. R.J. Baldessarini, L. Tondo, P. Davis, M. Pompili, F.K. Goodwin, and J. Hennen Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review Bipolar Disord. 8 2006 625 639
4. R.J. Baldessarini, J. Undurraga, G.H. Vazquez, L. Tondo, P. Salvatore, K. Ha, H.M. Khalsa, B. Lepri, T.H. Ha, J.S. Chang, M. Tohen, and E. Vieta Predominant recurrence polarity among 928 adult international bipolar I disorder patients Acta Psychiatr. Scand. 125 2012 293 302
5. M.S. Bauer, G.F. Kirk, C. Gavin, and W.O. Williford Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study J. Affect. Disord. 65 2001 231 241
6. J.R. Calabrese, M.A. Frye, R. Yang, T.A. Ketter, and Armodafinil Treatment Trial Study Network Efficacy and safety of armodafinil for the adjunctive treatment of major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled; multicenter trial J. Clin. Psychiatry 75 2014 1054 1061
7. J.R. Calabrese, J.D. Guelfi, and C. Perdrizet-Chevallier Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data Bipolar Disord. 9 2007 628 635
8. J.R. Calabrese, R.M. Hirschfeld, M.A. Frye, and M.L. Reed Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample J. Clin. Psychiatry 65 2004 1499 1504
9. J.R. Calabrese, T.A. Ketter, J.M. Youakim, J.M. Tiller, R. Yang, and M.A. Frye Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study J. Clin. Psychiatry 71 2010 1363 1370
10. C.A. Czeisler, J.K. Walsh, K.A. Wesnes, S. Arora, and T. Roth Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study Mayo Clin. Proc. 84 2009 958 972
11. M. Fornaro, M.J. McCarthy, D. De Berardis, C. De Pasquale, M. Tabaton, M. Martino, S. Colicchio, C.I. Cattaneo, E. D'Angelo, and P. Fornaro Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study Neuropsychiatr. Dis. Treat. 9 2013 243 251
12. M.A. Frye, J. Amchin, M. Bauer, C. Adler, R. Yang, and T.A. Ketter Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments Int. J. Bipolar Disord. 3 2015 34
13. M.A. Frye, H. Grunze, T. Suppes, S.L. McElroy, P.E. Keck Jr., J. Walden, G.S. Leverich, L.L. Altshuler, S. Nakelsky, S. Hwang, J. Mintz, and R.M. Post A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression Am. J. Psychiatry 164 2007 1242 1249
14. M.A. Frye, M.L. Prieto, W.V. Bobo, S. Kung, M. Veldic, R.D. Alarcon, K.M. Moore, D.S. Choi, J.M. Biernacka, and S.J. Tye Current landscape, unmet needs, and future directions for treatment of bipolar depression J. Affect. Disord. 169 Suppl. 1 2014 S17 S23
15. X. Gonda, M. Pompili, G. Serafini, F. Montebovi, S. Campi, P. Dome, T. Duleba, P. Girardi, and Z. Rihmer Suicidal behavior in bipolar disorder: epidemiology, characteristics and major risk factors J. Affect. Disord. 143 2012 16 26
16. J.R. Harsh, R. Hayduk, R. Rosenberg, K.A. Wesnes, J.K. Walsh, S. Arora, G.E. Niebler, and T. Roth The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy Curr. Med. Res. Opin. 22 2006 761 774
17. M. Hirshkowitz, J.E. Black, K. Wesnes, G. Niebler, S. Arora, and T. Roth Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome Respir. Med. 101 2007 616 627
18. L.L. Judd, H.S. Akiskal, P.J. Schettler, J. Endicott, J. Maser, D.A. Solomon, A.C. Leon, J.A. Rice, and M.B. Keller The long-term natural history of the weekly symptomatic status of bipolar I disorder Arch. Gen. Psychiatry 59 2002 530 537
19. D.E. Kemp Managing the side effects associated with commonly used treatments for bipolar depression J. Affect. Disord. 169 Suppl. 1 2014 S34 S44
20. T.A. Ketter, S. Miller, B. Dell'Osso, J.R. Calabrese, M.A. Frye, and L. Citrome Balancing benefits and harms of treatments for acute bipolar depression J. Affect. Disord 169 Suppl. 1 2014 S24 S33
21. T.A. Ketter, R. Yang, and M.A. Frye Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder J. Affect. Disord. 181 2015 87 91
22. R.W. Kupka, L.L. Altshuler, W.A. Nolen, T. Suppes, D.A. Luckenbaugh, G.S. Leverich, M.A. Frye, P.E. Keck Jr., S.L. McElroy, H. Grunze, and R.M. Post Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder Bipolar Disord. 9 2007 531 535
23. G.S. Leverich, L.L. Altshuler, M.A. Frye, T. Suppes, S.L. McElroy, P.E. Keck Jr., R.W. Kupka, K.D. Denicoff, W.A. Nolen, H. Grunze, M.I. Martinez, and R.M. Post Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers Am. J. Psychiatry 163 2006 232 239
24. K.R. Merikangas, H.S. Akiskal, J. Angst, P.E. Greenberg, R.M. Hirschfeld, M. Petukhova, and R.C. Kessler Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication Arch. Gen. Psychiatry 64 2007 543 552
25. K.R. Merikangas, R. Jin, J.P. He, R.C. Kessler, S. Lee, N.A. Sampson, M.C. Viana, L.H. Andrade, C. Hu, E.G. Karam, M. Ladea, M.E. Medina-Mora, Y. Ono, J. Posada-Villa, R. Sagar, J.E. Wells, and Z. Zarkov Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative Arch. Gen. Psychiatry 68 2011 241 251
26. A.A. Nierenberg Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression Psychother. Psychosom. 78 2009 391 393
27. Nuvigil [package insert], 2015. Teva Pharmaceuticals USA, Inc. North Wales, PA.
28. R.M. Post, K.D. Denicoff, G.S. Leverich, L.L. Altshuler, M.A. Frye, T.M. Suppes, A.J. Rush, P.E. Keck Jr., S.L. McElroy, D.A. Luckenbaugh, C. Pollio, R. Kupka, and W.A. Nolen Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method J. Clin. Psychiatry 64 2003 680 690
29. T. Roth, D. White, W. Schmidt-Nowara, K.A. Wesnes, G. Niebler, S. Arora, and J. Black Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults Clin. Ther. 28 2006 689 706
30. G. Sepede, G. Di Iorio, M. Lupi, F. Sarchione, T. Acciavatti, F. Fiori, R. Santacroce, G. Martinotti, F. Gambi, and M. Di Giannantonio Bupropion as an add-on therapy in depressed bipolar disorder type I patients with comorbid cocaine dependence Clin. Neuropharmacol. 37 2014 17 21
31. M.M. Sidor, and G.M. Macqueen Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis J. Clin. Psychiatry 72 2011 156 167
32. World Health Organization, 2008. The global burden of disease. 2004 update. Available at: (http://www.who.int/healthinfo/global-burden-disease/2004-report-update/en/index.html) (accessed 23.04.15).
33. L.N. Yatham, E. Vieta, G.M. Goodwin, M. Bourin, C. de Bodinat, J. Laredo, and J. Calabrese Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial Br. J. Psychiatry 208 2016 78 86